Digital Media Solutions Announced 1-for-15 Reverse Stock Split Effective Aug 28

Digital Media Solutions, Inc. (NYSE:DMS) today announced that its Board of Directors approved a reverse stock split of the Company’s Class A common stock and Class B common stock at a ratio of 1-for-15. Earlier, on

Digital Media Solutions, Inc. (NYSE:DMS) today announced that its Board of Directors approved a reverse stock split of the Company’s Class A common stock and Class B common stock at a ratio of 1-for-15. Earlier, on April 28, 2023, a majority of the Company’s stockholders approved a reverse stock split subject to the Board of Directors determining the final ratio. The reverse stock split is expected to be effective after market close on August 28, 2023 (the “Effective Time”). The Company’s Class A common stock will begin trading on a split-adjusted basis on the New York Stock Exchange (NYSE) at the market open on August 29, 2023.

At the Effective Time, every 15 issued and outstanding shares of the Company’s Class A common stock and Class B common stock will be converted automatically into one share of the Company’s Class A common stock and Class B common stock, respectively, without any change in the par value per share. Once effective, the reverse stock split will reduce the number of shares of Class A common stock issued and outstanding from approximately 40.9 million to approximately 2.7 million and Class B common stock issued and outstanding from approximately 25.1 million to approximately 1.7 million.

Total
0
Shares
Related Posts
Read More

Corcept Therapeutics Provides Financial Update And Announces $200M Stock Repurchase Program; Sees Q4 Revenue $135.4M Vs $127.85M Est.; FY23 Revenue $482.4M Vs $474.82M Est.; FY24 Revenue $600M–$630M Vs $513.85M Est.

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating

CORT

Read More

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrollingOvaprene has the potential to be the

DARE